GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Omnicell Inc (NAS:OMCL) » Definitions » Debt-to-EBITDA
中文

Omnicell (Omnicell) Debt-to-EBITDA : 427.64 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Omnicell Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Omnicell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11 Mil. Omnicell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $604 Mil. Omnicell's annualized EBITDA for the quarter that ended in Dec. 2023 was $1 Mil. Omnicell's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 427.64.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Omnicell's Debt-to-EBITDA or its related term are showing as below:

OMCL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.78   Med: 3.27   Max: 10.12
Current: 10.12

During the past 13 years, the highest Debt-to-EBITDA Ratio of Omnicell was 10.12. The lowest was 0.78. And the median was 3.27.

OMCL's Debt-to-EBITDA is ranked worse than
89.74% of 419 companies
in the Healthcare Providers & Services industry
Industry Median: 2.57 vs OMCL: 10.12

Omnicell Debt-to-EBITDA Historical Data

The historical data trend for Omnicell's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omnicell Debt-to-EBITDA Chart

Omnicell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 4.93 3.10 6.37 10.12

Omnicell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.22 122.14 4.83 5.61 427.64

Competitive Comparison of Omnicell's Debt-to-EBITDA

For the Health Information Services subindustry, Omnicell's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omnicell's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Omnicell's Debt-to-EBITDA falls into.



Omnicell Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Omnicell's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.518 + 603.572) / 60.69
=10.12

Omnicell's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.518 + 603.572) / 1.436
=427.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Omnicell  (NAS:OMCL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Omnicell Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Omnicell's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Omnicell (Omnicell) Business Description

Traded in Other Exchanges
Address
2625 Augustine Drive, Suite 301, Santa Clara, CA, USA, 95054
Omnicell Inc provides automation and business analytics software for healthcare providers. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.
Executives
Kaushik Ghoshal director 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Christine Marie Mellon officer: EVP, Chief People Officer 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Randall A Lipps director, officer: President and CEO 1101 EAST MEADOW DR, PALO ALTO CA 94303
Nchacha Etta officer: EVP & CFO 4220 NORTH FREEWAY, FORT WORTH TX 76137
Joanne B Bauer director 1400 HOLCOMB BRIDGE ROAD, ROSWELL GA 30076-2199
Scott Peter Seidelmann officer: EVP, Chief Commercial Officer 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Peter J. Kuipers officer: Executive V.P. CFO 590 E. MIDDLEFEILD ROAD, MOUNTAIN VIEW CA 94043
Mary Garrett director ETHAN ALLEN DRIVE, DANBURY CT 06811
Manley Corey J officer: SR. VP & CHIEF LEGAL OFFICER 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Dan S Johnston officer: V.P., Legal & General Counsel
Joseph Brian Spears officer: Chief Accounting Officer & VP 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
James T Judson officer: VP Finance & Acting CFO C/O OMNICELL, INC., 1201 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043
Robin Gene Seim officer: V.P., Finance & CFO 1201 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043
Edward Peter Bousa director 280 CONGRESS STREET, BOSTON MA 02210
Nhat H Ngo officer: VP, Strategy & Business Dev. 490 NORTH WIGET LANE, WALNUT CREEK CA 94598

Omnicell (Omnicell) Headlines